Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Studies have reported an increased risk of developing diabetes in subjects receiving statins versus placebo. Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. We studied 252 hyperlipidemic men and women who had been randomized to receive atorvastatin 80 mg/day or rosuvastatin 40 mg/day during a 6-week period. Atorvastatin and rosuvastatin were both highly effective in lowering the low-density lipoprotein cholesterol and triglyceride levels, with rosuvastatin more effective than atorvastatin in increasing high-density lipoprotein cholesterol. Atorvastatin and rosuvastatin at the maximum dosage both significantly (p <0.05) increased the median insulin levels by 5.2% and 8.7%, respectively, from baseline. However, only atorvastatin increased the glycated albumin levels from baseline (+0.8% for atorvastatin vs -0.7% for rosuvastatin, p = 0.002). Both atorvastatin and rosuvastatin caused significant (p <0.001) and similar median reductions in the C-reactive protein level of -40% and -26% compared to the baseline values. However, no statistically significant difference was found between the 2 groups in the adiponectin changes from baseline (-1.5% vs -4.9%, p = 0.15). In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels.
Jean Mayer United States Department of Agriculture, Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA.
Nuntakorn
N
Thongtang
Masumi
M
Ai
Seiko
S
Otokozawa
Thomas V
TV
Himbergen
Bela F
BF
Asztalos
Katsuyuki
K
Nakajima
Evan
E
Stein
Peter H
PH
Jones
Ernst J
EJ
Schaefer
D052242:Adiponectin / Q000097:blood; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood; D003920:Diabetes Mellitus / Q000139:chemically induced; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000009:adverse effects*; D005947:Glucose / Q000378:metabolism*; D017127:Glycation End Products, Advanced; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006706:Homeostasis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006949:Hyperlipidemias / Q000097:blood; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000068718:Rosuvastatin Calcium; D012709:Serum Albumin / Q000032:analysis; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood; D000093423:Glycated Serum Albumin
D052242:Adiponectin; D015415:Biomarkers; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D017127:Glycation End Products, Advanced; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007328:Insulin; D011743:Pyrimidines; D011758:Pyrroles; D012709:Serum Albumin; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D000069059:Atorvastatin; D005947:Glucose; D000093423:Glycated Serum Albumin
Am J Cardiol. 2003 Jul 15;92(2):152-60
12860216
Clin Chem. 2010 Jun;56(6):967-76
20431054
Clin Chem. 1995 May;41(5):717-23
7729051
Clin Chim Acta. 2002 Oct;324(1-2):61-71
12204426
J Lab Clin Med. 1998 Sep;132(3):195-201
9735925
Int J Clin Pract. 2009 Sep;63(9):1308-13
19691613
Lancet. 2005 Oct 8;366(9493):1267-78
16214597
J Am Coll Cardiol. 2006 Aug 1;48(3):438-45
16875966
Atherosclerosis. 2009 Jul;205(1):197-201
19200542
Clin Chim Acta. 2004 Aug 16;346(2):135-43
15256314
J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):167-74
20147603
Am J Cardiol. 2007 Mar 1;99(5):681-5
17317371
Curr Med Res Opin. 2008 May;24(5):1359-62
18384710
Diabetologia. 2006 Aug;49(8):1881-92
16685502
Diabetes Res Clin Pract. 2010 Jan;87(1):98-107
19913318
N Engl J Med. 2008 Nov 20;359(21):2195-207
18997196
J Lipid Res. 2009 Apr;50(4):730-9
19043140
Am J Cardiol. 2008 Feb 1;101(3):315-8
18237592
Clin Chim Acta. 2009 Aug;406(1-2):71-4
19465013
Clin Chim Acta. 2006 Sep;371(1-2):163-8
16712824
Lancet. 2010 Feb 27;375(9716):735-42
20167359
Clin Ther. 2004 Sep;26(9):1388-99
15531001
J Am Coll Cardiol. 2010 Mar 23;55(12):1209-1216
20298928